4D Molecular Therapeutics (NASDAQ:FDMT) Insider David Kirn Sells 114,746 Shares

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider David Kirn sold 114,746 shares of the stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $10.47, for a total value of $1,201,390.62. Following the transaction, the insider directly owned 942,485 shares in the company, valued at $9,867,817.95. The trade was a 10.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

David Kirn also recently made the following trade(s):

• On Monday, June 1st, David Kirn sold 1,922 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.02, for a total value of $19,258.44.

4D Molecular Therapeutics Price Performance

NASDAQ:FDMT opened at $11.60 on Wednesday. 4D Molecular Therapeutics, Inc. has a 1-year low of $3.68 and a 1-year high of $12.34. The company has a 50-day moving average of $9.47 and a 200 day moving average of $9.13. The firm has a market cap of $606.40 million, a PE ratio of -4.51 and a beta of 2.75.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. The business had revenue of $3.05 million during the quarter, compared to the consensus estimate of $2.59 million. Sell-side analysts anticipate that 4D Molecular Therapeutics, Inc. will post -3.8 EPS for the current fiscal year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Several hedge funds have recently added to or reduced their stakes in FDMT. Janus Henderson Group PLC lifted its holdings in shares of 4D Molecular Therapeutics by 164.4% in the 4th quarter. Janus Henderson Group PLC now owns 4,635,875 shares of the company’s stock valued at $34,726,000 after buying an additional 2,882,508 shares during the period. State Street Corp grew its holdings in 4D Molecular Therapeutics by 197.5% during the fourth quarter. State Street Corp now owns 2,688,880 shares of the company’s stock worth $20,167,000 after acquiring an additional 1,785,106 shares during the period. RA Capital Management L.P. raised its position in 4D Molecular Therapeutics by 23.9% during the fourth quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company’s stock valued at $42,399,000 after acquiring an additional 1,090,000 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its position in 4D Molecular Therapeutics by 605.8% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,235,156 shares of the company’s stock valued at $9,264,000 after acquiring an additional 1,060,156 shares in the last quarter. Finally, Evergreen Quality Fund GP Ltd. acquired a new position in 4D Molecular Therapeutics in the fourth quarter valued at approximately $7,136,000. 99.27% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Royal Bank Of Canada boosted their target price on shares of 4D Molecular Therapeutics from $32.00 to $35.00 and gave the stock an “outperform” rating in a research report on Thursday, March 19th. HC Wainwright reiterated a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Friday, March 20th. Wall Street Zen lowered 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. The Goldman Sachs Group set a $33.00 price objective on 4D Molecular Therapeutics in a research note on Friday, May 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Monday, April 20th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $29.88.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.